University Hospitals Researchers Initiate Gene Therapy Trial in Patients with Advanced Skin Cancer
Friday, February 29, 2008 (190 reads)
Gene Therapy treatment aimed to boost immune system to fight deadly disease.
CLEVELAND, December 10, 2007 − Researchers at the Ireland Cancer Center of University Hospitals Case Medical Center are the first in the region to have joined a nationwide clinical trial to evaluate the effectiveness of a gene therapy in patients with advanced melanoma which is aimed to help a patient’s own immune system fight their cancer. The gene therapy is termed Allovectin-7 Ò, and is injected directly into the cancer while it is still in the body in order to make it appear foreign to the immune system. Previous studies using the gene therapy have shown that injection of a single site of cancer can train the immune system to fight other areas of the disease in the body which have not been injected with the gene.
 Read More |
|
First Patient Treated with Novel “First-in-Class” Anti-Cancer Drug; Drug Developed by Ireland Cancer Center Researchers
Monday, February 25, 2008 (573 reads)
CLEVELAND – A new anti-cancer drug developed at the Ireland Cancer Center of University Hospitals Case Medical Center and Case Western Reserve University was used for the first time to treat a cancer patient. The Phase One study at the Ireland Cancer Center of TRC102, a novel anti-cancer drug intended to reverse resistance to chemotherapy by targeting a specific DNA repair pathway, has the potential to improve the lives of many patients.
“This new therapy has the promise of overcoming a major mechanism of drug resistance which is good news for cancer patients,” says Panos Savvides, MD, oncologist with the Ireland Cancer Center, assistant professor of medicine at Case Western Reserve University and primary investigator for the trial. “Resistance to chemotherapy prevents many patients from benefiting, but this new “first-in-class” agent, used in combination with Temodar®, uniquely reverses resistance to chemotherapy.”
Read More |
|
University Hospitals first in Northeast Ohio to utilize novel stem cell therapy; Cardiac navigation system improves heart function
Friday, February 22, 2008 (481 reads)
CLEVELAND – University Hospitals Case Medical Center’s Heart & Vascular Institute is the first hospital in Northeast Ohio to use the NOGA XP Cardiac Navigation System to inject a patient’s own stem cells into his/her heart to treat angina. The innovative cardiac mapping system allows physicians to deliver the stem cell therapy into damaged areas of the heart with pinpoint accuracy.
The NOGA XP system, made by Biologics Delivery System of Cordis/Johnson & Johnson, records electrical and mechanical signals during a catheterization procedure and generates a highly precise, three-dimensional image of the heart. Based on color-coded images, the University Hospitals Case Medical Center (UHCMC) team is able to determine the optimal areas to deliver stem cell injections into the patient’s heart to generate growth of new blood vessels to alleviate angina.
 Read More |
|
University Hospitals to Provide Corporate Health Services for Lincoln Electric
Monday, February 18, 2008 (490 reads)
CLEVELAND – University Hospitals Corporate Health has been chosen to provide comprehensive work-related healthcare services to the Lincoln Electric Co., the worldwide leader in the field of welding and cutting products. Lincoln Electric employs more than 3,000 people at its headquarters and operations in Euclid and a plant in Mentor, Ohio.
Under the agreement, a University Hospitals (UH) physician and nurse practitioner will be located part-time at Lincoln Electric directing all facets of occupational health for the company from post-offer testing and exams, OSHA-mandated surveillance, respiratory exams, wellness and prevention programs, ergonomic risk evaluations along with the coordination and case management of external medical provider services.
Read More |
|